CytomX Therapeutics (CTMX) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

CTMX Stock Forecast

CytomX Therapeutics stock forecast is as follows: an average price target of $3.47 (represents a 218.35% upside from CTMX’s last price of $1.09) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.

CTMX Price Target

The average price target for CytomX Therapeutics (CTMX) is $3.47 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $3.68 to $3.25. This represents a potential 218.35% upside from CTMX's last price of $1.09.

CTMX Analyst Ratings

Buy

According to 5 Wall Street analysts, CytomX Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for CTMX stock is 0 'Strong Buy' (0.00%), 3 'Buy' (60.00%), 2 'Hold' (40.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

CytomX Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Nov 08, 2024	Etzer Darout	BMO Capital	$3.68	$1.09	237.61%	237.61%
Nov 08, 2024	Joseph Catanzaro	Piper Sandler	$3.25	$1.09	198.17%	198.17%
Aug 09, 2024	Etzer Darout	BMO Capital	$3.56	$1.18	201.69%	226.61%
May 27, 2024	Joseph Catanzaro	Piper Sandler	$3.50	$1.75	100.00%	221.10%
May 09, 2024	Etzer Darout	BMO Capital	$3.59	$4.19	-14.32%	229.36%
May 09, 2024	Robert Driscoll	Wedbush	$8.00	$2.40	233.46%	633.94%
May 05, 2024	Roger Song	Jefferies	$8.00	$4.46	79.57%	633.94%
Mar 12, 2024	Roger Song	Jefferies	$2.50	$2.15	16.28%	129.36%
Mar 12, 2024	Etzer Darout	BMO Capital	$3.25	$2.15	51.16%	198.17%
Jan 06, 2023		BMO Capital	$3.20	$1.79	78.77%	193.58%
Nov 14, 2022		BMO Capital	$2.60	$1.29	101.55%	138.53%

The latest CytomX Therapeutics stock forecast, released on Nov 08, 2024 by Etzer Darout from BMO Capital, set a price target of $3.68, which represents a 237.61% increase from the stock price at the time of the forecast ($1.09), and a 237.61% increase from CTMX last price ($1.09).

CytomX Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	-	2	9
Avg Price Target	-	$3.47	$4.37
Last Closing Price	$1.09	$1.09	$1.09
Upside/Downside	-100.00%	218.35%	300.92%

In the current month, the average price target of CytomX Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to CytomX Therapeutics's last price of $1.09. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Nov 08, 2024	Piper Sandler	Overweight	Overweight	Hold
Sep 13, 2024	H.C. Wainwright	Neutral	Neutral	Hold
Aug 09, 2024	BMO Capital	Market Perform	Market Perform	Hold
Jun 27, 2024	H.C. Wainwright	Neutral	Neutral	Hold
May 27, 2024	Piper Sandler	Neutral	Overweight	Upgrade
May 09, 2024	H.C. Wainwright	Neutral	Neutral	Hold
May 09, 2024	BMO Capital	Market Perform	Market Perform	Hold
May 05, 2024	Jefferies		Buy	Upgrade
Nov 08, 2023	Wedbush		Outperform	Upgrade
Jan 06, 2023	BMO Capital	Market Perform	Market Perform	Hold
Nov 14, 2022	BMO Capital		Market Perform	Downgrade
Jul 07, 2022	Piper Sandler		Neutral	Downgrade

CytomX Therapeutics's last stock rating was published by Piper Sandler on Nov 08, 2024. The company gave CTMX a "Overweight" rating, the same as its previous rate.

CytomX Therapeutics Financial Forecast

CytomX Therapeutics Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	$26.61M	$26.38M	$24.72M	$23.50M	$946.00K	$16.91M	$18.16M	$17.14M	$19.73M	$17.59M	$16.29M	$15.97M	$16.37M	$17.79M	$16.61M	$49.59M	$8.28M	$10.71M
Avg Forecast	$57.93M	$54.50M	$51.27M	$48.23M	$12.38M	$20.64M	$20.39M	$20.89M	$13.53M	$17.10M	$20.00M	$19.35M	$19.60M	$13.34M	$13.68M	$19.91M	$18.07M	$18.15M	$18.11M	$21.25M	$19.57M	$18.38M	$16.96M	$18.28M	$16.09M	$17.14M	$52.99M	$20.98M	$17.37M	$18.07M
High Forecast	$103.03M	$96.92M	$91.18M	$85.78M	$22.01M	$36.71M	$36.27M	$29.18M	$25.79M	$30.41M	$35.57M	$34.41M	$26.09M	$13.34M	$24.33M	$35.41M	$32.14M	$18.15M	$18.11M	$21.25M	$19.57M	$18.38M	$16.96M	$18.28M	$16.09M	$17.14M	$52.99M	$20.98M	$17.37M	$18.07M
Low Forecast	$7.49M	$7.05M	$6.63M	$6.24M	$1.60M	$2.67M	$2.64M	$11.05M	$4.77M	$2.21M	$2.59M	$2.50M	$12.58M	$13.34M	$1.77M	$2.58M	$2.34M	$18.15M	$18.11M	$21.25M	$19.57M	$18.38M	$16.96M	$18.28M	$16.09M	$17.14M	$52.99M	$20.98M	$17.37M	$18.07M
# Analysts	1	1	1	1	1	1	1	3	5	4	3	3	6	3	3	3	4	4	4	4	3	3	3	3	11	15	9	9	8	8
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	1.36%	1.98%	1.81%	1.18%	0.05%	0.93%	1.00%	0.81%	1.01%	0.96%	0.96%	0.87%	1.02%	1.04%	0.31%	2.36%	0.48%	0.59%

CytomX Therapeutics's average Quarter revenue forecast for Mar 24 based on 3 analysts is $19.35M, with a low forecast of $2.50M, and a high forecast of $34.41M. CTMX's average Quarter revenue forecast represents a -27.27% decrease compared to the company's last Quarter revenue of $26.61M (Dec 23).

CytomX Therapeutics EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	3	5	4	3	3	6	3	3	3	4	4	4	4	3	3	3	3	11	15	9	9	8	8
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	$-120.00K	$3.12M	$-2.74M	$-5.06M	$-28.08M	$-23.32M	$-24.13M	$-23.36M	$-25.55M	$-21.90M	$-18.57M	$-14.88M	$-14.04M	$-14.06M	$-15.06M	$-1.07M	$-35.27M	$-23.02M
Avg Forecast	$-44.25M	$-41.63M	$-39.16M	$-36.84M	$-9.45M	$-15.77M	$-15.58M	$-15.96M	$-10.34M	$-13.06M	$-15.28M	$-31.41M	$-14.97M	$-10.19M	$-10.45M	$-28.55M	$-21.00M	$-12.71M	$-12.68M	$-22.57M	$-13.71M	$-12.87M	$-11.88M	$-18.71M	$-11.26M	$-12.00M	$-37.10M	$-2.47M	$-12.16M	$-12.65M
High Forecast	$-5.72M	$-5.38M	$-5.07M	$-4.77M	$-1.22M	$-2.04M	$-2.01M	$-8.44M	$-3.64M	$-1.69M	$-1.98M	$-25.13M	$-9.61M	$-10.19M	$-1.35M	$-22.84M	$-16.80M	$-12.71M	$-12.68M	$-18.06M	$-13.71M	$-12.87M	$-11.88M	$-14.97M	$-11.26M	$-12.00M	$-37.10M	$-1.97M	$-12.16M	$-12.65M
Low Forecast	$-78.70M	$-74.04M	$-69.65M	$-65.53M	$-16.81M	$-28.04M	$-27.70M	$-22.29M	$-19.70M	$-23.23M	$-27.17M	$-37.69M	$-19.93M	$-10.19M	$-18.59M	$-34.26M	$-25.20M	$-12.71M	$-12.68M	$-27.08M	$-13.71M	$-12.87M	$-11.88M	$-22.45M	$-11.26M	$-12.00M	$-37.10M	$-2.96M	$-12.16M	$-12.65M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.01%	-0.31%	0.26%	0.18%	1.34%	1.83%	1.90%	1.04%	1.86%	1.70%	1.56%	0.80%	1.25%	1.17%	0.41%	0.43%	2.90%	1.82%

6 analysts predict CTMX's average Quarter EBITDA for Dec 23 to be $-14.97M, with a high of $-9.61M and a low of $-19.93M. This is -579.39% lower than CytomX Therapeutics's previous annual EBITDA (Sep 23) of $3.12M.

CytomX Therapeutics Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	3	5	4	3	3	6	3	3	3	4	4	4	4	3	3	3	3	11	15	9	9	8	8
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	$837.00K	$2.99M	$-1.09M	$-969.00K	$-26.58M	$-22.65M	$-23.63M	$-23.80M	$-26.23M	$-22.58M	$-19.24M	$-15.55M	$-14.70M	$-14.71M	$-15.68M	$12.21M	$-35.46M	$-23.70M
Avg Forecast	$-20.60M	$-20.08M	$-19.68M	$-19.86M	$-13.97M	$-7.07M	$-10.03M	$-8.46M	$-16.70M	$-14.68M	$-8.50M	$-32.31M	$-4.11M	$-16.07M	$-16.11M	$-29.38M	$-21.99M	$-25.87M	$-31.67M	$-23.22M	$-29.40M	$-26.55M	$-27.10M	$-19.55M	$-42.74M	$-40.43M	$13.28M	$28.18M	$-39.88M	$-44.39M
High Forecast	$2.72M	$2.65M	$2.60M	$2.62M	$1.84M	$931.57K	$1.32M	$-2.12M	$-834.84K	$1.94M	$1.12M	$-25.85M	$16.46M	$2.12M	$2.12M	$-23.50M	$-17.59M	$-25.87M	$-31.67M	$-18.58M	$-29.40M	$-26.55M	$-27.10M	$-15.64M	$-42.74M	$-40.43M	$13.28M	$33.81M	$-39.88M	$-44.39M
Low Forecast	$-41.45M	$-40.41M	$-39.60M	$-39.96M	$-28.10M	$-14.22M	$-20.18M	$-12.69M	$-44.25M	$-29.54M	$-17.11M	$-38.78M	$-24.69M	$-32.33M	$-32.41M	$-35.25M	$-26.39M	$-25.87M	$-31.67M	$-27.87M	$-29.40M	$-26.55M	$-27.10M	$-23.46M	$-42.74M	$-40.43M	$13.28M	$22.54M	$-39.88M	$-44.39M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-0.20%	-0.19%	0.07%	0.03%	1.21%	0.88%	0.75%	1.03%	0.89%	0.85%	0.71%	0.80%	0.34%	0.36%	-1.18%	0.43%	0.89%	0.53%

CytomX Therapeutics's average Quarter net income forecast for Mar 24 is $-32.31M, with a range of $-38.78M to $-25.85M. CTMX's average Quarter net income forecast represents a -3960.54% decrease compared to the company's last Quarter net income of $837.00K (Dec 23).

CytomX Therapeutics SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	3	5	4	3	3	6	3	3	3	4	4	4	4	3	3	3	3	11	15	9	9	8	8
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	$7.79M	$6.81M	$7.40M	$7.98M	$10.07M	$10.49M	$11.75M	$10.54M	$9.46M	$11.09M	$9.39M	$9.23M	$9.14M	$8.63M	$8.68M	$9.57M	$9.22M	$8.46M
Avg Forecast	$30.86M	$29.04M	$27.31M	$25.70M	$6.59M	$11.00M	$10.86M	$11.13M	$7.21M	$9.11M	$10.66M	$14.26M	$10.44M	$7.11M	$7.29M	$12.97M	$13.68M	$9.67M	$9.65M	$10.25M	$10.42M	$9.79M	$9.03M	$11.60M	$8.57M	$9.12M	$28.22M	$11.17M	$9.25M	$9.62M
High Forecast	$54.89M	$51.64M	$48.58M	$45.70M	$11.73M	$19.56M	$19.32M	$15.54M	$13.74M	$16.20M	$18.95M	$17.12M	$13.90M	$7.11M	$12.96M	$15.56M	$16.42M	$9.67M	$9.65M	$12.30M	$10.42M	$9.79M	$9.03M	$13.92M	$8.57M	$9.12M	$28.22M	$11.17M	$9.25M	$9.62M
Low Forecast	$3.99M	$3.76M	$3.53M	$3.32M	$852.84K	$1.42M	$1.41M	$5.89M	$2.54M	$1.18M	$1.38M	$11.41M	$6.71M	$7.11M	$942.74K	$10.37M	$10.94M	$9.67M	$9.65M	$8.20M	$10.42M	$9.79M	$9.03M	$9.28M	$8.57M	$9.12M	$28.22M	$11.17M	$9.25M	$9.62M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.75%	0.96%	1.02%	0.62%	0.74%	1.09%	1.22%	1.03%	0.91%	1.13%	1.04%	0.80%	1.07%	0.95%	0.31%	0.86%	1.00%	0.88%

CytomX Therapeutics's average Quarter SG&A projection for Mar 24 is $14.26M, based on 3 Wall Street analysts, with a range of $11.41M to $17.12M. The forecast indicates a 83.09% rise compared to CTMX last annual SG&A of $7.79M (Dec 23).

CytomX Therapeutics EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	3	5	4	3	3	6	3	3	3	4	4	4	4	3	3	3	3	11	15	9	9	8	8
EPS	-	-	-	-	-	-	-	-	-	-	-	-	$0.01	$0.04	$-0.02	$-0.01	$-0.40	$-0.34	$-0.36	$-0.36	$-0.40	$-0.35	$-0.30	$-0.26	$-0.32	$-0.32	$-0.34	$0.27	$-0.78	$-0.52
Avg Forecast	$-0.24	$-0.24	$-0.23	$-0.23	$-0.16	$-0.08	$-0.12	$-0.10	$-0.20	$-0.17	$-0.10	$-0.10	$-0.05	$-0.19	$-0.19	$-0.11	$-0.24	$-0.30	$-0.37	$-0.36	$-0.35	$-0.31	$-0.32	$-0.35	$-0.50	$-0.48	$0.16	$-0.45	$-0.47	$-0.52
High Forecast	$0.03	$0.03	$0.03	$0.03	$0.02	$0.01	$0.02	$-0.02	$-0.01	$0.02	$0.01	$0.01	$0.19	$0.02	$0.02	$0.01	$0.03	$-0.30	$-0.37	$-0.36	$-0.35	$-0.31	$-0.32	$-0.35	$-0.50	$-0.48	$0.16	$-0.45	$-0.47	$-0.52
Low Forecast	$-0.49	$-0.47	$-0.46	$-0.47	$-0.33	$-0.17	$-0.24	$-0.15	$-0.52	$-0.35	$-0.20	$-0.21	$-0.29	$-0.38	$-0.38	$-0.22	$-0.47	$-0.30	$-0.37	$-0.36	$-0.35	$-0.31	$-0.32	$-0.35	$-0.50	$-0.48	$0.16	$-0.45	$-0.47	$-0.52
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-0.26%	-0.20%	0.09%	0.13%	1.70%	1.12%	0.96%	1.01%	1.15%	1.12%	0.94%	0.75%	0.63%	0.67%	-2.17%	-0.61%	1.65%	0.99%

According to 3 Wall Street analysts, CytomX Therapeutics's projected average Quarter EPS for Mar 24 is $-0.10, with a low estimate of $-0.21 and a high estimate of $0.01. This represents a -923.15% decrease compared to CTMX previous annual EPS of $0.01 (Dec 23).

CytomX Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
SPRO	Spero Therapeutics	$1.04	$10.00	861.54%	Buy
TIL	Instil Bio	$21.69	$150.00	591.56%	Hold
NXTC	NextCure	$0.90	$3.00	233.33%	Buy
CTMX	CytomX Therapeutics	$1.13	$3.47	207.08%	Buy
NUVB	Nuvation Bio	$2.81	$7.00	149.11%	Buy
ASMB	Assembly Biosciences	$14.28	$35.50	148.60%	Buy
ACHL	Achilles Therapeutics	$0.97	$2.00	106.19%	Buy

CTMX Forecast FAQ

Is CytomX Therapeutics a good buy?

Yes, according to 5 Wall Street analysts, CytomX Therapeutics (CTMX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 60.00% of CTMX's total ratings.

What is CTMX's price target?

CytomX Therapeutics (CTMX) average price target is $3.47 with a range of $3.25 to $3.68, implying a 218.35% from its last price of $1.09. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will CytomX Therapeutics stock go up soon?

According to Wall Street analysts' prediction for CTMX stock, the company can go up by 218.35% (from the last price of $1.09 to the average price target of $3.47), up by 237.61% based on the highest stock price target, and up by 198.17% based on the lowest stock price target.

Can CytomX Therapeutics stock reach $2?

CTMX's average twelve months analyst stock price target of $3.47 supports the claim that CytomX Therapeutics can reach $2 in the near future.

What are CytomX Therapeutics's analysts' financial forecasts?

CytomX Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $74.3M (high $124.16M, low $17.96M), average EBITDA is $-56.756M (high $-13.719M, low $-94.847M), average net income is $-39.522M (high $1.98M, low $-75.19M), average SG&A $39.59M (high $66.15M, low $9.57M), and average EPS is $-0.464 (high $0.0232, low $-0.882). CTMX's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $211.92M (high $376.91M, low $27.41M), average EBITDA is $-162M (high $-20.94M, low $-288M), average net income is $-80.229M (high $10.58M, low $-161M), average SG&A $112.91M (high $200.82M, low $14.6M), and average EPS is $-0.942 (high $0.124, low $-1.895).

Did the CTMX's actual financial results beat the analysts' financial forecasts?

Based on CytomX Therapeutics's last annual report (Dec 2023), the company's revenue was $101.21M, beating the average analysts forecast of $66.53M by 52.12%. Apple's EBITDA was $-6.484M, missing the average prediction of $-64.166M by -89.89%. The company's net income was $-569K, missing the average estimation of $-65.668M by -99.13%. Apple's SG&A was $30.02M, missing the average forecast of $37.81M by -20.60%. Lastly, the company's EPS was $0, missing the average prediction of $-0.537 by -100.00%. In terms of the last quarterly report (Dec 2023), CytomX Therapeutics's revenue was $26.61M, beating the average analysts' forecast of $19.6M by 35.76%. The company's EBITDA was $-120K, missing the average prediction of $-14.971M by -99.20%. CytomX Therapeutics's net income was $837K, missing the average estimation of $-4.114M by -120.34%. The company's SG&A was $7.79M, missing the average forecast of $10.44M by -25.40%. Lastly, the company's EPS was $0.0124, missing the average prediction of $-0.0483 by -125.68%